Stock Insights: Endologix, IAC/InterActiveCorp, Zynga, Apple, VeriFone June 12th

Endologix Inc. (NASDAQ:ELGX): After meeting with Endologix’s management, Oppenheimer reports that abdominal aortic aneurysm market volumes/pricing remain solid. The firm thinks the Street is still underestimating the value of the company’s Nelix treatment in that market and it recommends buying the stock.

IAC/InterActiveCorp. (NASDAQ:IACI): Oppenheimer expects InterActiveCorp’s growth to remain strong in Q2 and Q3, and the firm maintains an Outperform rating on the stock.

Zynga (NASDAQ:ZNGA): Cowen said Zynga’s (NASDAQ:ZNGA) social gaming DAU’s declined significantly for the second consecutive month and nearly all of its title’s declined significantly. The firm feels interest in Facebook (NASDAQ:FB) gaming may have reached a negative inflection point as they believe consumer preferences may be switching to mobile games. Shares of Zynga are Neutral rated.

Apple Inc. (NASDAQ:AAPL): BMO Capital believes that Apple’s new MacBook portfolio increases its competitive advantage over PC manufacturers. The firm thinks that Apple is sustaining its product leadership in the notebook sector and it maintains a $695 target and Outperform rating on the stock.

VeriFone Systems, Inc (NYSE:PAY): Citigroup believes the unfavorable jury verdict in an ongoing patent infringement lawsuit in Texas that VeriFone disclosed in a regulatory filing last night will not help the ongoing negative sentiment in the stock. However, Citi continues to view the recent weakness in shares of VeriFone as a long-term buying opportunity and maintains a Buy rating on the stock with a $55 price target.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.